OverviewSuggest Edit
Aeglea BioTherapeutics is a biotechnology company committed to developing enzyme-based therapeutics. It specializes in the field of amino acid metabolism to treat rare genetic diseases and cancer.
| Type | Public | |
| Founded | 2013 | |
| HQ | Austin, TX, US | Map |
| Website | aeglea.com |
Recent NewsAll News
- Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights
- Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics
- Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
- Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East
Key People/Management at Aeglea
Anthony Quinn
President & Chief Executive Officer, Director
Michael C. Hanley
Chief Commercial Officer
Eric Bradford
Chief Development Officer
Scott W. Rowlinson
Vice President of Research
Joseph E. Tyler
Vice President of Manufacturing
Leslie Sloan
Chief Operating Officer
Aeglea Office Locations
Aeglea has an office in Austin
Austin, TX, US (HQ)
805 Las Cimas Pkwy #100
Aeglea Financials and Metrics
Aeglea Revenue
| USD | |
|---|---|
Net income (Q1, 2021) | (18.2m) |
EBIT (Q1, 2021) | (18.2m) |
Market capitalization (12-Nov-2021) | 359.5m |
Closing stock price (12-Nov-2021) | 7.0 |
Cash (31-Mar-2021) | 80.2m |
EV | 284.6m |
Aeglea's current market capitalization is $359.5 m.
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.5m | 2.4m | ||||||||
General and administrative expense | 2.9m | 2.9m | 3.3m | 3.3m | 3.8m | 4.3m | 4.5m | 4.7m | 5.7m | 6.4m |
R&D expense | 6.9m | 9.1m | 8.9m | 14.4m | 14.8m | 17.8m | 14.6m | 16.9m | 12.5m | 11.9m |
Operating expense total | 9.8m | 12.0m | 12.2m | 17.7m | 18.6m | 22.1m | 19.0m | 21.6m | 18.1m | 18.2m |
Annual
Quarterly
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (8.1m) | (17.5m) | (29.4m) | (17.2m) | (35.2m) | (56.8m) | (18.7m) | (40.1m) | (58.2m) | (18.2m) |
Depreciation and Amortization | 70.0k | 145.0k | 221.0k | 100.0k | 207.0k | 312.0k | 154.0k | 376.0k | 627.0k | 355.0k |
Accounts Payable | 396.0k | 579.0k | 727.0k | 2.3m | 2.1m | 1.8m | 262.0k | 1.3m | (539.0k) | (376.0k) |
Cash From Operating Activities | (7.4m) | (16.5m) | (25.0m) | (15.8m) | (32.2m) | (49.4m) | (21.7m) | (41.1m) | (58.6m) | (19.5m) |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 127.0k |
Financial Leverage | 1.1 x |
Aeglea Cybersecurity Score
Aeglea Environment, Social & Governance (ESG) Ratings
Aeglea Online and Social Media Presence
178 Twitter followers
Aeglea has 178 Twitter Followers. The number of followers has increased 4.4% month over month and increased 14% quarter over quarter
Aeglea's Trends
Twitter Engagement Stats for @aegleabio
252
Tweets
47
Following
178
Followers
15
Tweets last 30 days
1.8
Avg. likes per Tweet
73.3%
Tweets with engagement
Aeglea News and Updates
November 04, 2021
Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights
AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third...
November 04, 2021
Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics
AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that seven abstracts will be presented...
May 10, 2021
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its first quarter 2021 financial...
March 22, 2021
Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, and Immedica Pharma AB (Immedica) today announced the license and supply agreement for pegzilarginase, a no…
February 24, 2021
Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Sara Brownstein to its board of directors. Ms. Brownstein serves as a p…
February 03, 2021
Aeglea BioTherapeutics Announces Transition of Chief Financial Officer
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the company's chief financial officer, Charles N. York II, will be leaving the company…
Aeglea Blogs
December 17, 2020
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
AUSTIN, Texas , Dec. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the appointment of Alison
November 24, 2020
Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference
Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference
Content Import
Tue, 11/24/2020 - 16:41
Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference
11/24/20
This release is a backfill from a News…
November 17, 2020
Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
AUSTIN, Texas , Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in fireside
November 05, 2020
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
Received U.S. Orphan Drug and Positive Opinion for EU Orphan Drug Designations for ACN00177 Continued Progress in Arginase 1 Deficiency Patient Identification and Engagement Efforts AUSTIN, Texas , Nov. 5, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc.
October 05, 2020
Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings
AUSTIN, Texas , Oct. 5, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the presentation of a poster on
September 02, 2020
Aeglea BioTherapeutics to Participate in September Investment Conferences
AUSTIN, Texas , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in
Aeglea Frequently Asked Questions
When was Aeglea founded?
Aeglea was founded in 2013.
Who are Aeglea key executives?
Aeglea's key executives are Anthony Quinn, Michael C. Hanley and Eric Bradford.
How many employees does Aeglea have?
Aeglea has 76 employees.
Who are Aeglea competitors?
Competitors of Aeglea include Horizon Therapeutics, Erytech Pharma and Embera NeuroTherapeutics.
Where is Aeglea headquarters?
Aeglea headquarters is located at 805 Las Cimas Pkwy #100, Austin.
Where are Aeglea offices?
Aeglea has an office in Austin.
How many offices does Aeglea have?
Aeglea has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies